Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study

被引：0

作者：

Kato, T. ^{[1
]}

Kotani, D. ^{[2
]}

Takashima, A. ^{[3
]}

Satoh, T. ^{[4
]}

Masuishi, T. ^{[5
]}

Komatsu, Y. ^{[6
]}

Shiozawa, M. ^{[7
]}

Esaki, T.

Izawa, N. ^{[8
]}

Takeuchi, S. ^{[9
]}

Bando, H. ^{[10
]}

Iwasa, S. ^{[11
]}

Hasegawa, H. ^{[12
]}

Yamaguchi, T. ^{[13
]}

Taniguchi, H. ^{[5
]}

Yamada, S. ^{[14
]}

Yoshino, T. ^{[2
]}

机构：

[1] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Osaka, Japan

[2] Natl Canc Ctr Hosp East, Kashiwa, Japan

[3] Natl Canc Ctr Hosp, Dept Gastrointestinal Med Oncol, Chuo, Japan

[4] Kinki Univ, Dept Med Oncol, Sch Med, Osaka, Japan

[5] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Japan

[6] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Japan

[7] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Japan

[8] St Marianna Univ, Dept Clin Oncol, Sch Med, Kawasaki, Japan

[9] Kanazawa Univ Hosp, Kanazawa, Japan

[10] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Onc, Kashiwa, Japan

[11] Natl Canc Ctr, Tokyo, Japan

[12] Natl Hosp Org Osaka Natl Hosp, Osaka, Japan

[13] Osaka Med & Pharmaceut Univ Hosp, Takatsuki, Japan

[14] Ono Pharmaceut, Osaka, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-23

引用

页码：S21 / S22

页数：2

共 50 条

[31] Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer
Huijberts, Sanne C. F. A.
van Geel, Robin M. J. M.
Bernards, Rene
Beijnen, Jos H.
Steeghs, Neeltje
FUTURE ONCOLOGY, 2020, 16 (06) : 161 - 174
[32] Beacon Crc: a Randomized, Phase 3 Study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BiNI) vs. Choice of Either Irinotecan or Folfiri Plus Cetux in BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC)
Vogel, Arndt
Hegewisch-Becker, Susanna
Prager, Gerald
Folprecht, Gunnar
Stahl, Michael
Kopetz, Scott
Grothey, Axel
van Cutsetn, Eric
Yaeger, Rona
Wasan, Harpreet
Yoshino, Takayuki
Desai, Jayesh
Ciardello, Fortunato
Gollerkeri, Ashwin
Maharry, Kati
Loupakis, Fotios
Hong, Y.
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia-Alfons, Pilar
Sandor, Victor
Christy-Bittel, Farina
Anderson, Lisa
Tabernero, Josep
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 55 - 55
[33] Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer
Stammler, Romain
Gallois, Claire
Taieb, Julien
Duong, Jean-Paul
Karras, Alexandre
Thervet, Eric
Lazareth, Helene
EUROPEAN JOURNAL OF CANCER, 2021, 147 : 60 - 62
[34] ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT BINIMETINIB FOR BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER: MANAGEMENT OF ADVERSE EVENTS FROM A RANDOMIZED, 3-ARM, PHASE 3 STUDY VS. THE CHOICE OF EITHER IRINOTECAN OR FOLFIRI PLUS CETUXIMAB (BEACON CRC)
Trevino, Tracy
Kopetz, Scott
Grothey, Axel
Yaeger, Rona
Sandor, Victor
Velez, Lydia
ONCOLOGY NURSING FORUM, 2020, 47 (02)
[35] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet Singh
Yoshino, Takayuki
Desai, Jayesh
Ciardiello, Fortunato
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia-Alfonso, Pilar
Gollerkeri, Ashwin
Maharry, Kati
Christy-Bittel, Janna
Keir, Christopher Hunt
Pickard, Michael D.
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[36] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet Singh
Yoshino, Takayuki
Desai, Jayesh
Ciardiello, Fortunato
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Kyrre Guren, Tormod
Arkenau, Hendrik-Tobias
Garcia-Alfonso, Pilar
Gollerkeri, Ashwin
Maharry, Kati
Christy-Bittel, Janna
Hunt Keir, Christopher
Pickard, Michael D.
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[37] A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Baik, Christina
Cheng, Michael L.
Dietrich, Martin
Gray, Jhanelle E.
Karim, Nagla A.
ADVANCES IN THERAPY, 2024, 41 (07) : 2586 - 2605
[38] Clinical research progress on BRAF V600E-mutant advanced colorectal cancer
Zeng, Chuanxiu
Wang, Mengchao
Xie, Shuqi
Wang, Na
Wang, Zhen
Yi, Dan
Kong, Fanming
Chen, Liwei
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (17) : 16111 - 16121
[39] Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
Ros, Javierd
Saoudi, Nadia
Baraibar, Iosune
Salva, Francesc
Tabernero, Josep
Elez, Elena
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
[40] A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
Riely, Gregory J.
Smit, Egbert F.
Ahn, Myung-Ju
Felip, Enriqueta
Ramalingam, Suresh S.
Tsao, Anne
Johnson, Melissa
Gelsomino, Francesco
Esper, Raymond
Nadal, Ernest
Offin, Michael
Provencio, Mariano
Clarke, Jeffrey
Hussein, Maen
Otterson, Gregory A.
Dagogo-Jack, Ibiayi
Goldman, Jonathan W.
Morgensztern, Daniel
Alcasid, Ann
Usari, Tiziana
Wissel, Paul
Wilner, Keith
Pathan, Nuzhat
Tonkovyd, Svitlana
Johnson, Bruce E.
FUTURE ONCOLOGY, 2024, 20 (16) : 1047 - 1055

← 1 2 3 4 5 →